Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization

Acinetobacter infections have increased and gained attention because of the organism’s prolonged environmental survival and propensity to develop antimicrobial drug resistance. The effect of multidrug-resistant (MDR) Acinetobacter infection on clinical outcomes has not been reported. A retrospective, matched cohort investigation was performed at 2 Baltimore hospitals to examine outcomes of patients with MDR Acinetobacter infection compared with patients with susceptible Acinetobacter infections and patients without Acinetobacter infections. Multivariable analysis controlling for severity of illness and underlying disease identified an independent association between patients with MDR Acinetobacter infection (n = 96) and increased hospital and intensive care unit length of stay compared with 91 patients with susceptible Acinetobacter infection (odds ratio [OR] 2.5, 95% confidence interval [CI] 1.2–5.2 and OR 2.1, 95% CI 1.0–4.3] respectively) and 89 uninfected patients (OR 2.5, 95% CI 1.2–5.4 and OR 4.2, 95% CI 1.5–11.6] respectively). Increased hospitalization associated with MDR Acinetobacter infection emphasizes the need for infection control strategies to prevent cross-transmission in healthcare settings.

[1]  Jonathan R Edwards,et al.  Overview of nosocomial infections caused by gram-negative bacilli. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  W. Bilker,et al.  Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. , 2005, Archives of internal medicine.

[3]  S. Cosgrove,et al.  The Impact of Methicillin Resistance in Staphylococcus aureus Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges , 2005, Infection Control & Hospital Epidemiology.

[4]  L. See,et al.  Risk factors of mortality for nosocomial pneumonia: importance of initial anti‐microbial therapy , 2005, International journal of clinical practice.

[5]  Y. Carmeli,et al.  Reference Group Choice and Antibiotic Resistance Outcomes , 2004, Emerging infectious diseases.

[6]  P Gastmeier,et al.  Surveillance of nosocomial infections , 2004 .

[7]  J. Rello,et al.  Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: A matched cohort study* , 2003, Critical care medicine.

[8]  D. Christmann,et al.  Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. , 2003, Infection control and hospital epidemiology.

[9]  R. Zaragoza,et al.  The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  M. Villegas,et al.  Acinetobacter Outbreaks, 1977–2000 , 2003, Infection Control & Hospital Epidemiology.

[11]  T. Perl,et al.  Effect of Nosocomial Vancomycin-Resistant Enterococcal Bacteremia on Mortality, Length of Stay, and Costs , 2003, Infection Control & Hospital Epidemiology.

[12]  F. Colardyn,et al.  Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study , 2003, Intensive Care Medicine.

[13]  P. Hsueh,et al.  Pandrug-Resistant Acinetobacter baumannii Causing Nosocomial Infections in a University Hospital, Taiwan , 2002, Emerging infectious diseases.

[14]  A. Glatt,et al.  Completely Resistant Acinetobacter baumannii Strains , 2002, Infection Control & Hospital Epidemiology.

[15]  M. Niederman.  Impact of antibiotic resistance on clinical outcomes and the cost of care , 2001, Critical care medicine.

[16]  Ronald N. Jones,et al.  Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  W. Schaffner,et al.  An Outbreak of Acinetobacter baumannii: The Importance of Cross-Transmission , 2000, Infection Control & Hospital Epidemiology.

[18]  D. Landman,et al.  Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  J. Garnacho-Montero,et al.  Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. , 1999, Critical care medicine.

[20]  J. Heritage,et al.  Exceptional desiccation tolerance of Acinetobacter radioresistens. , 1998, The Journal of hospital infection.

[21]  R. Gaynes,et al.  Accuracy of Reporting Nosocomial Infections In Intensive-Care–Unit Patients to the National Nosocomial Infections Surveillance System: A Pilot Study , 1998, Infection Control & Hospital Epidemiology.

[22]  J. Chastre,et al.  Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  M. Safar,et al.  Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  W. Knaus.  The APACHE III Prognostic System , 1992 .

[25]  W. Knaus,et al.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.

[26]  Y. Hirai.  Survival of bacteria under dry conditions; from a viewpoint of nosocomial infection. , 1991, The Journal of hospital infection.

[27]  D. Rasley.  Surveillance of nosocomial infections , 1989, Critical care nursing quarterly.

[28]  R. Wenzel,et al.  Gram-negative bacilli as nontransient flora on the hands of hospital personnel , 1987, Journal of clinical microbiology.

[29]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[30]  B. Simmons,et al.  Guideline for isolation precautions in hospitals , 1984, American Journal of Infection Control.

[31]  E. Hultén,et al.  Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. , 2004, MMWR. Morbidity and mortality weekly report.

[32]  Yung-Chang Chen,et al.  APACHE III scoring system in critically III patients with acute renal failure requiring dialysis , 2002 .

[33]  P. Hsueh,et al.  Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. , 2002, Emerging infectious diseases.

[34]  J. Garner,et al.  Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. , 1996, Infection control and hospital epidemiology.

[35]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[36]  L. Glass,et al.  Dialysis and transplantation: a mothers' group. , 1976, Social work in health care.